Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Roadblocks in Cation Diffusion Pathways: Implications of Phase Boundaries for Li-Ion Diffusivity in an Intercalation Cathode Material.

Luo Y, De Jesus LR, Andrews JL, Parija A, Fleer N, Robles DJ, Mukherjee PP, Banerjee S.

ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30901-30911. doi: 10.1021/acsami.8b10604. Epub 2018 Aug 28.

PMID:
30106560
2.

Hydrogen Bonding Controls the Structural Evolution in Perovskite-Related Hybrid Platinum(IV) Iodides.

Evans HA, Fabini DH, Andrews JL, Koerner M, Preefer MB, Wu G, Wudl F, Cheetham AK, Seshadri R.

Inorg Chem. 2018 Aug 20;57(16):10375-10382. doi: 10.1021/acs.inorgchem.8b01597. Epub 2018 Aug 3.

3.

Mapping Catalytically Relevant Edge Electronic States of MoS2.

Parija A, Choi YH, Liu Z, Andrews JL, De Jesus LR, Fakra SC, Al-Hashimi M, Batteas JD, Prendergast D, Banerjee S.

ACS Cent Sci. 2018 Apr 25;4(4):493-503. doi: 10.1021/acscentsci.8b00042. Epub 2018 Apr 3.

4.

Structure-Induced Switching of the Band Gap, Charge Order, and Correlation Strength in Ternary Vanadium Oxide Bronzes.

Tolhurst TM, Andrews JL, Leedahl B, Marley PM, Banerjee S, Moewes A.

Chemistry. 2017 Jul 21;23(41):9846-9856. doi: 10.1002/chem.201700962. Epub 2017 Jun 27.

PMID:
28543976
5.

Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia.

Matosin N, Newell KA, Quidé Y, Andrews JL, Teroganova N, Green MJ, Fernandez F.

Brain Imaging Behav. 2018 Apr;12(2):509-517. doi: 10.1007/s11682-017-9712-0.

PMID:
28405888
6.

Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies.

Andrews JL, Goodfellow FJ, Matosin N, Snelling MK, Newell KA, Huang XF, Fernandez-Enright F.

J Psychiatr Res. 2017 Jul;90:31-39. doi: 10.1016/j.jpsychires.2017.01.009. Epub 2017 Jan 18.

PMID:
28226265
7.

The Dependency of Nematic and Twist-bend Mesophase Formation on Bend Angle.

Mandle RJ, Archbold CT, Sarju JP, Andrews JL, Goodby JW.

Sci Rep. 2016 Nov 7;6:36682. doi: 10.1038/srep36682.

8.

Neurodevelopmental Expression Profile of Dimeric and Monomeric Group 1 mGluRs: Relevance to Schizophrenia Pathogenesis and Treatment.

Lum JS, Fernandez F, Matosin N, Andrews JL, Huang XF, Ooi L, Newell KA.

Sci Rep. 2016 Oct 10;6:34391. doi: 10.1038/srep34391.

9.

Molecular evidence of synaptic pathology in the CA1 region in schizophrenia.

Matosin N, Fernandez-Enright F, Lum JS, Engel M, Andrews JL, Gassen NC, Wagner KV, Schmidt MV, Newell KA.

NPJ Schizophr. 2016 Jun 29;2:16022. doi: 10.1038/npjschz.2016.22. eCollection 2016.

10.

Contrasting 1D tunnel-structured and 2D layered polymorphs of V2O5: relating crystal structure and bonding to band gaps and electronic structure.

Tolhurst TM, Leedahl B, Andrews JL, Marley PM, Banerjee S, Moewes A.

Phys Chem Chem Phys. 2016 Jun 21;18(23):15798-806. doi: 10.1039/c6cp02096h. Epub 2016 May 27.

PMID:
27230816
11.

Are We There Yet? Exploring the Impact of Translating Cognitive Tests for Dementia Using Mobile Technology in an Aging Population.

Ruggeri K, Maguire Á, Andrews JL, Martin E, Menon S.

Front Aging Neurosci. 2016 Mar 17;8:21. doi: 10.3389/fnagi.2016.00021. eCollection 2016.

12.

Lingo-1: a novel target in therapy for Alzheimer's disease?

Fernandez-Enright F, Andrews JL.

Neural Regen Res. 2016 Jan;11(1):88-9. doi: 10.4103/1673-5374.175048. No abstract available.

13.

Genetic variants in Nogo receptor signaling pathways may be associated with early life adversity in schizophrenia susceptibility.

Andrews JL, Fernandez-Enright F.

BBA Clin. 2014 Dec 9;3:36-43. doi: 10.1016/j.bbacli.2014.11.008. eCollection 2015 Jun.

14.

Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function.

Matosin N, Green MJ, Andrews JL, Newell KA, Fernandez-Enright F.

Neuroreport. 2016 Jan 6;27(1):33-8. doi: 10.1097/WNR.0000000000000491.

PMID:
26555035
15.

A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders.

Andrews JL, Fernandez-Enright F.

Neurosci Biobehav Rev. 2015 Sep;56:97-114. doi: 10.1016/j.neubiorev.2015.06.009. Epub 2015 Jul 2. Review.

PMID:
26143511
16.

Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats.

Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:91-7. doi: 10.1016/j.pnpbp.2015.06.003. Epub 2015 Jun 10.

PMID:
26071990
17.

Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.

Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, Newell KA.

Schizophr Res. 2015 Aug;166(1-3):212-8. doi: 10.1016/j.schres.2015.05.001. Epub 2015 Jun 2.

PMID:
26048293
18.

Apolar bimesogens and the incidence of the twist-bend nematic phase.

Mandle RJ, Davis EJ, Archbold CT, Voll CC, Andrews JL, Cowling SJ, Goodby JW.

Chemistry. 2015 May 26;21(22):8158-67. doi: 10.1002/chem.201500423. Epub 2015 Apr 20.

PMID:
25900846
19.

Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation.

Matosin N, Fernandez-Enright F, Fung SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, Newell KA.

Acta Neuropathol. 2015 Jul;130(1):119-29. doi: 10.1007/s00401-015-1411-6. Epub 2015 Mar 17.

PMID:
25778620
20.

Investigation of genetic variants in ubiquitin enzyme genes involved in the modulation of neurodevelopmental processes: a role in schizophrenia susceptibility?

Andrews JL, Fernandez-Enright F.

Genet Res (Camb). 2014 Nov 24;96:e15. doi: 10.1017/S0016672314000184.

PMID:
25578144
21.

Novel implications of Lingo-1 and its signaling partners in schizophrenia.

Fernandez-Enright F, Andrews JL, Newell KA, Pantelis C, Huang XF.

Transl Psychiatry. 2014 Jan 21;4:e348. doi: 10.1038/tp.2013.121.

22.

In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.

Jafari S, Huang XF, Andrews JL, Fernandez-Enright F.

PLoS One. 2013 Dec 11;8(12):e80979. doi: 10.1371/journal.pone.0080979. eCollection 2013.

23.

Genetic ablation of myelin protein zero-like 3 in mice increases energy expenditure, improves glycemic control, and reduces hepatic lipid synthesis.

Czyzyk TA, Andrews JL, Coskun T, Wade MR, Hawkins ED, Lockwood JF, Varga G, Sahr AE, Chen Y, Brozinick JT, Kikly K, Statnick MA.

Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E282-92. doi: 10.1152/ajpendo.00228.2013. Epub 2013 May 28.

24.

The role and function of cadherins in the mammary gland.

Andrews JL, Kim AC, Hens JR.

Breast Cancer Res. 2012 Feb 8;14(1):203. Review.

25.

CLOCK and BMAL1 regulate MyoD and are necessary for maintenance of skeletal muscle phenotype and function.

Andrews JL, Zhang X, McCarthy JJ, McDearmon EL, Hornberger TA, Russell B, Campbell KS, Arbogast S, Reid MB, Walker JR, Hogenesch JB, Takahashi JS, Esser KA.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19090-5. doi: 10.1073/pnas.1014523107. Epub 2010 Oct 18.

26.

A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione, a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity.

Szewczyk JR, Laudeman CP, Sammond DM, Villeneuve M, Minick DJ, Grizzle MK, Daniels AJ, Andrews JL, Ignar DM.

Bioorg Med Chem. 2010 Mar 1;18(5):1822-33. doi: 10.1016/j.bmc.2010.01.049. Epub 2010 Jan 25.

PMID:
20172734
27.

Parathyroid hormone synergizes with non-cyclic AMP pathways to activate the cyclic AMP response element.

Murrills RJ, Andrews JL, Samuel RL, Coleburn VE, Bhat BM, Bhat RA, Bex FJ, Bodine PV.

J Cell Biochem. 2009 Apr 1;106(5):887-95. doi: 10.1002/jcb.22057.

PMID:
19180574
28.

Identification of the circadian transcriptome in adult mouse skeletal muscle.

McCarthy JJ, Andrews JL, McDearmon EL, Campbell KS, Barber BK, Miller BH, Walker JR, Hogenesch JB, Takahashi JS, Esser KA.

Physiol Genomics. 2007 Sep 19;31(1):86-95. Epub 2007 Jun 5.

29.

Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation.

Miller BH, McDearmon EL, Panda S, Hayes KR, Zhang J, Andrews JL, Antoch MP, Walker JR, Esser KA, Hogenesch JB, Takahashi JS.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3342-7. Epub 2007 Feb 20.

30.

Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules.

Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, Littleton TR, McCoy DC, Kenakin TP, Andrews JL, Ammala C, Fornwald JA, Ignar DM, Jenkinson S.

Br J Pharmacol. 2006 Jul;148(5):619-28. Epub 2006 May 15.

31.

In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity.

Murrills RJ, Matteo JJ, Samuel RL, Andrews JL, Bhat BM, Coleburn VE, Kharode YP, Bex FJ.

Bone. 2004 Dec;35(6):1263-72.

PMID:
15589208
32.

Aging does not alter the mechanosensitivity of the p38, p70S6k, and JNK2 signaling pathways in skeletal muscle.

Hornberger TA, Mateja RD, Chin ER, Andrews JL, Esser KA.

J Appl Physiol (1985). 2005 Apr;98(4):1562-6. Epub 2004 Sep 10.

33.

African American adolescents' experiences with unplanned pregnancy and elective abortion.

Andrews JL, Boyle JS.

Health Care Women Int. 2003 May-Jun;24(5):414-33.

PMID:
12916146
34.

Regulation of TNF-alpha secretion by a specific melanocortin-1 receptor peptide agonist.

Ignar DM, Andrews JL, Jansen M, Eilert MM, Pink HM, Lin P, Sherrill RG, Szewczyk JR, Conway JG.

Peptides. 2003 May;24(5):709-16.

PMID:
12895657
35.

Carbohydrate loading and supplementation in endurance-trained women runners.

Andrews JL, Sedlock DA, Flynn MG, Navalta JW, Ji H.

J Appl Physiol (1985). 2003 Aug;95(2):584-90. Epub 2003 Apr 25.

36.

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.

Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI.

J Biol Chem. 2003 Mar 28;278(13):11303-11. Epub 2002 Dec 19.

37.

Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector.

Andrews JL, Shirley PS, Iverson WO, Sherer AD, Markovits JE, King L, Lyons RM, Kaleko M, Connelly S.

Hum Gene Ther. 2002 Jul 20;13(11):1331-6.

PMID:
12162815
38.

Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop.

Jankova L, Harrop SJ, Saunders DN, Andrews JL, Bertram KC, Gould AR, Baker MS, Curmi PM.

J Biol Chem. 2001 Nov 16;276(46):43374-82. Epub 2001 Aug 23.

39.

Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.

Andrews JL, Kadan MJ, Gorziglia MI, Kaleko M, Connelly S.

Mol Ther. 2001 Mar;3(3):329-36.

40.

Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.

Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, Cameron C, Hough C, Notley C, Lillicrap D, Kaleko M, Connelly S.

Blood. 2001 Jan 1;97(1):107-13.

41.

Development of a facile method for high throughput screening with reporter gene assays.

Goetz AS, Andrews JL, Littleton TR, Ignar DM.

J Biomol Screen. 2000 Oct;5(5):377-84.

PMID:
11080697
42.

Development of class-switched, affinity-matured monoclonal antibodies following a 7-day immunization schedule.

Bynum J, Andrews JL, Ellis B, Kull FC Jr, Austin EA, Kilpatrick KE.

Hybridoma. 1999 Oct;18(5):407-11.

PMID:
10600027
43.

In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector.

Roy S, Shirley PS, Connelly S, Andrews JL, Kayda DB, Gardner JM, Kaleko M.

Haemophilia. 1999 Sep;5(5):340-8.

PMID:
10583516
44.

Detection of cyclophosphamide-induced mutations at the Hprt but not the lacI locus in splenic lymphocytes of exposed mice.

Walker VE, Andrews JL, Upton PB, Skopek TR, deBoer JG, Walker DM, Shi X, Sussman HE, Gorelick NJ.

Environ Mol Mutagen. 1999;34(2-3):167-81.

PMID:
10529741
45.

Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice.

Gorelick NJ, Andrews JL, deBoer JG, Young R, Gibson DP, Walker VE.

Environ Mol Mutagen. 1999;34(2-3):154-66.

PMID:
10529740
46.

In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.

Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, Kaloss M, Tinlin S, Cameron C, Notley C, Hough C, Lillicrap D, Kaleko M, Connelly S.

Hum Gene Ther. 1999 Jul 20;10(11):1791-802.

PMID:
10446919
47.
48.

Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.

Connelly S, Andrews JL, Gallo-Penn AM, Tagliavacca L, Kaufman RJ, Kaleko M.

Thromb Haemost. 1999 Feb;81(2):234-9.

PMID:
10063998
49.

Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.

Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J, Hoyer L, Kadan MJ, Gorziglia MI, Trapnell BC, McClelland A, Kaleko M.

Blood. 1998 May 1;91(9):3273-81.

50.

Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.

Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, Onori J, Kost T, Emerson DL.

Clin Exp Metastasis. 1998 Jan;16(1):9-20.

PMID:
9502073

Supplemental Content

Loading ...
Support Center